New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
09:12 EDTNAVBNavidea Biopharmaceuticals 1.542M share Secondary priced at $3.10
Ladenburg acted as sole book running manager for the offering.
News For NAVB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
08:02 EDTNAVBNavidea: Data for Menocept CD206 demonstrates potential to impact KS tumor cells
Navidea Biopharmaceuticals reported data at the American Association of Cancer Research Annual Meeting 2015 demonstrating that the Manocept molecule selectively binds to, and is continuously internalized by, tumor-associated macrophages and Kaposiís sarcoma, or KS, tumor cells in a preclinical model. Preliminary results from a clinical study also demonstrated that a single, subcutaneous injection of Technetium Tc 99m tilmanocept, an FDA-approved Manocept-based imaging agent, detects and localizes in KS tumors and the lymph nodes involved in draining the KS tumor fields. Collectively, the data demonstrate the potential for Manocept-based molecules to be used therapeutically to treat Kaposiís sarcoma. Manocept is designed to target CD206, which is expressed on TAMs and KS tissue. Modulation, including killing or modification of macrophage and KS expression profiles, represents a potential for a paradigm-shifting immunotherapeutic strategy.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use